Donate For Public and Patients Store Search

F084 - Fractional Laser and Light-based Technologies

Saturday, March 2; 3:30 PM - 5:30 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Discuss the current indications, limitations, and potential for fractional laser, light-based and energy-based devices in dermatology.
  • Identify possible side effects and complications of fractionated skin resurfacing and rejuvenation procedures and develop strategies to prevent and treat them.
  • Develop a working algorithm for the clinical use of fractionated devices, including preoperative assessment, intraoperative treatment protocol, and postoperative follow-up.


This session is appropriate for experienced and potential users of fractional laser and light technologies. Specific treatment protocols will be outlined and tips to optimize clinical outcomes will be shared. The expert faculty will use evidence-based approaches to examine the strengths and weaknesses of current fractional technology. A review of fractionated laser skin resurfacing and rejuvenation in varying skin tones and conditions as well as a discussion of future technologic applications will provide the attendee with the latest advancements in the fields.


  • Alster, Tina S., MD: A Method – C(OB); Cearna, Inc – A(OB); Collagen P.I.N. – A(NC); Galderma USA – I(Grants/Research Funding); Hair Sanity – SH(ST); Home Skinovations – C(ST); Merz Aesthetics – A(H); Revance Therapeutics, Inc. – I(Grants/Research Funding);
  • Chan, Henry H.L., MD, PhD: AVAVA, LLC – B(Fees), B(IP); Basis Medical Technologies Inc – A(OB); Blossom Innovations, LLC – B(IP); Cutera, Inc. – I(EQ); Cynosure, Inc. – I(EQ), I(OB); Cytrellis Biosystems, Inc – SH(ST); Lumenis – O(H); McGraw-Hill Companies – O(IP); Novartis – O(H); Quanta System S.p.A – I(EQ); R2 Dermatology, Inc. – B(Fees), B(IP), I(Grants/Research Funding); sanofi-aventis – A(H), C(Fees); Syneron, Inc. – A(H), I(OB); Venus Concept – I(EQ);
  • Geronemus, Roy G., MD: Allergan, Inc – I(Grants/Research Funding); Allergan, Inc. – A(Grants/Research Funding); ArchiMedus – I(Grants/Research Funding); Candela Corporation – A(Grants/Research Funding), I(Grants/Research Funding); Cearna, Inc – A(Grants/Research Funding); Cynosure, Inc – A(Grants/Research Funding), I(Grants/Research Funding); Cytrellis Biosystems, Inc – A(Grants/Research Funding), I(ST), SH(ST); Endo Pharmaceuticals – I(Grants/Research Funding); Kerastem – I(Grants/Research Funding); Lutronic – A(Grants/Research Funding), I(Grants/Research Funding); Merz Aesthetics – I(Grants/Research Funding); Miramar Labs – I(Grants/Research Funding); New York Stem Cell Foundation – I(Grants/Research Funding); Revance Therapeutics, Inc. – I(Grants/Research Funding); Sciton Inc. – I(Grants/Research Funding); Sienna Biopharmaceuticals – I(Grants/Research Funding); Syneron Candela – A(Grants/Research Funding), I(Grants/Research Funding);
  • Green, Jeremy, MD: Aclaris Therapeutics Inc. – A(H); Allergan, Inc – A(H), I(Grants/Research Funding), SP(H); Bonti – A(H); Brickell Biotech, Inc. – I(Grants/Research Funding); Candesant Biomedical, Inc. – I(Grants/Research Funding), SH(ST); Clarisonic – A(H); Cutera, Inc. – SP(H); Cynosure, Inc. – SP(EQ); Endo International plc – A(H); Evolus, Inc. – A(H); Galderma Laboratories, L.P. – I(Grants/Research Funding), SP(H); Galderma USA – A(H); Lutronic – I(Grants/Research Funding); Merz Aesthetics – A(H), I(Grants/Research Funding), SP(H); Pulse Biosciences – I(Grants/Research Funding); Revance Therapeutics, Inc. – A(H), I(Grants/Research Funding); Sienna Labs, Inc. – A(H), I(Grants/Research Funding);
  • Manstein, Dieter, MD, PhD: AVAVA, LLC – C(H); Blossom Innovations, LLC – SH(ST); Cynosure, Inc. – O(IP); Everbloom LLC – F(ST); GME German Medical Engineering GmbH – SH(ST); Lumenis – A(H), I(Grants/Research Funding); R2 Dermatology, Inc. – C(Fees); Syneron Candela – O(IP); Zalea, LLC – SH(ST); Zeltiq Aesthetics – A(Fees), C(Fees), O(IP);
  • Waibel, Jill S., MD: Alma Lasers – SP(H); Aquavit Pharmaceuticals – I(SO); Candela Corporation – SP(H); Cutera, Inc. – I(Grants/Research Funding); Lumenis – I(H); Lutronics, Inc. – I(Grants/Research Funding); Michelson Diagnostics Ltd. – I(EQ); Regenx – C(Grants/Research Funding); Sciton Inc. – I(Grants/Research Funding); Sebacia, Inc. – I(Grants/Research Funding); Vivosight – I(Grants/Research Funding); Zeltiq Aesthetics – SP(H);
Saturday, March 2
3:30 PM
Dr. Geronemus / Introduction and Overview
3:35 PM
Dr. Geronemus / Fractional Lasers in Clinical Practice: Parameters and Pearls
3:55 PM
Dr. Waibel / Laser Scar Revision: Fractionated Technology and Combination Treatment
4:10 PM
Dr. Chan / Fractional Resurfacing Skin of Color
4:25 PM
Dr. Manstein / The future of Fractionated Laser and Light Technology
4:45 PM
Dr. Green / Non Laser Fractional Resurfacing and Rejuvenation
5:00 PM
Dr. Alster / Prevention and Management of side effects and complications
5:15 PM
All faculty / Questions and Answers
Event Details
  • Date
    Saturday, March 2
  • Time
    3:30 PM - 5:30 PM
  • Location
    Room 201
  • CME Credits
  • Type
  • Henry H.L. Chan, MD, PhD - Handout
  • Roy G. Geronemus, MD, FAAD
  • Dieter Manstein, MD, PhD
  • Jeremy Green, MD, FAAD
  • Jill S. Waibel, MD, FAAD
  • Tina S. Alster, MD, FAAD - Handout 1, Handout 2